Osimertinib/Tagrisso Price Revealed in 2025: Comparison of Original Drugs and Generic Drugs

Osimertinib/Tagressa is a targeted drug targeting EGFR mutation-positive non-small cell lung cancer (NSCLC). Since its launch, Osimertinib has become an important drug in the treatment of this type of cancer. However, due to its significant efficacy and high price, patients have to consider the financial burden when choosing a drug. According to differences in different regions and drug versions, the price of osimertinib varies greatly. Patients need to weigh the choice between the original drug and generic drugs according to their own circumstances.

In the Chinese market, the original drug of osimertinib has been launched and has been included in medical insurance, reducing the financial pressure on patients. Common specifications include80mg*30 tablets and 40mg*30 tablets, with the price per box ranging from approximately RMB 4,000 to RMB 6,000. Considering the long-term nature of the drug, medical insurance coverage can significantly reduce the cost of treatment for patients, making it affordable for more patients. As the medical insurance policy gradually improves, the price of drugs may be reduced to a certain extent in the future to provide more help to patients.

However, in the international market, the price of osimertinib is still relatively expensive, especially in the United States, Europe and other countries, where the selling price of the original drug usually exceeds10,000 US dollars per box, which brings a huge financial burden to patients. This price is mainly affected by factors such as research and development costs, production costs, market demand, and national medical policies. In addition, due to the complexity of the medical insurance system in these areas, patients may face a longer reimbursement approval process, which increases the financial pressure of treatment.

It is worth noting that with the expiration of drug patents and the launch of generic drugs, generic drugs of osimertinib have begun to circulate in some countries and regions. For example, in countries such as Laos and Bangladesh, the specifications of generic osimertinib produced are 80mg*30 tablets, and the price is about more than RMB 800 per box. This price has a significant advantage over the market price of the original drug, providing a more economical and affordable treatment option for patients with poor financial conditions. Although generic drugs are more attractive in terms of price, patients still need to ensure that the source of the drug is legal when purchasing to ensure the therapeutic effect.

Reference materials:https://go.drugbank.com/drugs/DB09330